Pimecrolimus — CAS 137071-32-0

Pimecrolimus is a calcineurin inhibitor used as a topical immunomodulator for the treatment of atopic dermatitis (eczema). It inhibits T-cell activation and cytokine release by binding to macrophilin-12, preventing calcineurin activation. Mediocon Inc manufactures Pimecrolimus API at its GMP-certified facility in Aurangabad, Maharashtra, India.

• Topical treatment of mild to moderate atopic dermatitis
• Second-line treatment for eczema in patients unresponsive to corticosteroids
• Treatment of seborrheic dermatitis and psoriasis
• Management of facial and intertriginous area eczema

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support